Immunovant (NASDAQ:IMVT) Stock Price Down 6.8% - Time to Sell?

Key Points

• Immunovant shares fell 6.8% to about $34.74 on Wednesday, with trading volume 53% below the average. The decline followed news that the company will discontinue IMVT-1402’s cutaneous lupus erythematosus program after its study failed to meet the primary endpoint or Immunovant’s continuation threshold.
• The study showed favorable safety and tolerability, along with positive but statistically insignificant trends across several clinical measures. Immunovant said its other development programs remain on track, increasing the importance of pipeline execution.
• Analyst sentiment remains broadly positive, with a “Moderate Buy” consensus and an average price target of $44 versus the recent share price. However, the company reported a wider-than-expected quarterly loss, and insiders sold roughly 98,359 shares worth $3.8 million over the past quarter.

Immunovant, Inc. (NASDAQ:IMVT - Get Free Report)'s stock price fell 6.8% on Wednesday . The stock traded as low as $35.34 and last traded at $34.7420. Approximately 701,117 shares changed hands during trading, a decline of 53% from the average session volume of 1,500,243 shares. The stock had previously closed at $37.29.

Immunovant News Summary

Here are the key news stories impacting Immunovant this week:

• Positive Sentiment: IMVT-1402 showed a favorable safety and tolerability profile consistent with prior studies. The company also said deeper IgG reductions were associated with improved clinical outcomes, while development timelines for its other programs remain on track. Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus
• Neutral Sentiment: The study produced positive trends across multiple clinical measures, but those trends did not reach statistical significance on the primary endpoint: percentage change from baseline in CLASI-A score at Week 12. Immunovant said the treatment’s safety profile remained favorable. Immunovant Announces Topline Results from Period 1 of Proof-of-Concept Trial
• Negative Sentiment: Because the CLE study missed its primary goal and failed to meet Immunovant’s internal threshold for continuation, the company will stop developing IMVT-1402 in CLE. The loss of this development opportunity increases focus on the success of the remaining pipeline, contributing to shares moving toward a more than three-month low. Immunovant Pulls Plug on Lupus Program After Study Misses Primary Goal

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on IMVT shares. JPMorgan Chase & Co. boosted their price objective on shares of Immunovant from $47.00 to $50.00 and gave the stock an "overweight" rating in a report on Tuesday, August 4th. Sanford C. Bernstein raised Immunovant to a "hold" rating in a report on Wednesday, July 29th. Cantor Fitzgerald restated an "overweight" rating on shares of Immunovant in a research note on Tuesday, August 25th. Citigroup upped their price target on Immunovant from $57.00 to $61.00 and gave the company a "buy" rating in a report on Tuesday, June 30th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Immunovant in a report on Monday, July 6th. Seven research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $44.00.

Immunovant Price Performance

The stock's 50-day simple moving average is $40.10 and its two-hundred day simple moving average is $33.78. The firm has a market capitalization of $7.16 billion, a P/E ratio of -12.32 and a beta of 0.81.

Immunovant (NASDAQ:IMVT - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.75) earnings per share for the quarter, missing the consensus estimate of ($0.63) by ($0.12). The business had revenue of $7.09 million during the quarter, compared to analyst estimates of $7.09 million. During the same period last year, the firm earned ($0.71) EPS. On average, analysts forecast that Immunovant, Inc. will post -2.96 earnings per share for the current fiscal year.

Insider Activity

In other Immunovant news, CFO Tiago Girão sold 10,000 shares of the company's stock in a transaction on Friday, June 26th. The stock was sold at an average price of $38.46, for a total value of $384,600.00. Following the transaction, the chief financial officer owned 247,596 shares of the company's stock, valued at $9,522,542.16. This represents a 3.88% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, COO Melanie Gloria sold 17,714 shares of the stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $38.31, for a total value of $678,623.34. Following the completion of the transaction, the chief operating officer directly owned 224,393 shares in the company, valued at approximately $8,596,495.83. This trade represents a 7.32% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 98,359 shares of company stock valued at $3,785,493. 1.90% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Immunovant

Several institutional investors and hedge funds have recently added to or reduced their stakes in IMVT. Empowered Funds LLC raised its position in Immunovant by 2.7% in the first quarter. Empowered Funds LLC now owns 14,556 shares of the company's stock worth $362,000 after acquiring an additional 381 shares in the last quarter. Corient Private Wealth LP boosted its position in shares of Immunovant by 1.8% during the 2nd quarter. Corient Private Wealth LP now owns 24,522 shares of the company's stock valued at $945,000 after purchasing an additional 442 shares in the last quarter. Swiss National Bank grew its stake in shares of Immunovant by 0.7% in the 1st quarter. Swiss National Bank now owns 159,400 shares of the company's stock worth $3,959,000 after purchasing an additional 1,100 shares during the last quarter. Wellington Management Group LLP raised its holdings in shares of Immunovant by 7.7% in the 2nd quarter. Wellington Management Group LLP now owns 30,722 shares of the company's stock worth $1,184,000 after purchasing an additional 2,197 shares in the last quarter. Finally, Handelsbanken Fonder AB raised its holdings in shares of Immunovant by 6.8% in the 2nd quarter. Handelsbanken Fonder AB now owns 34,500 shares of the company's stock worth $1,329,000 after purchasing an additional 2,200 shares in the last quarter. Hedge funds and other institutional investors own 47.08% of the company's stock.

About Immunovant

Immunovant, Inc NASDAQ: IMVT is a clinical-stage biopharmaceutical company developing therapies for patients with immune-mediated diseases. The company focuses on conditions in which disease-causing antibodies, or immunoglobulin G (IgG), play a central role, including autoimmune and inflammatory disorders.

Immunovant's lead product candidate is batoclimab, an investigational fully human monoclonal antibody designed to block the neonatal Fc receptor (FcRn). By inhibiting FcRn, batoclimab is intended to reduce circulating IgG antibodies that can contribute to autoimmune disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.